[Form 4] Health Catalyst, Inc Insider Trading Activity

Rhea-AI Filing Summary

Health Catalyst, Inc. (HCAT) filed a Form 4 disclosing that director Julie Larson-Green received an equity award of 36,231 restricted stock units (RSUs) on 07/09/2025 under the company’s 2019 Stock Option and Incentive Plan. Each RSU represents one share of common stock and vests in full on the earlier of (i) one year from the grant date or (ii) the next annual meeting of stockholders. The grant price is $0, reflecting a routine director compensation award rather than an open-market purchase.

Following the transaction, Larson-Green’s direct beneficial ownership rises to 111,251 shares. No derivative securities were reported. The filing is a standard annual equity grant to a non-employee director and does not involve cash consideration, sales, or option exercises.

Insights

Financial Analyst

TL;DR: Routine director RSU grant; immaterial to HCAT valuation.

The Form 4 records a standard board compensation grant of 36,231 RSUs to director Julie Larson-Green, boosting her direct holdings to 111,251 shares. There is no cash outflow for the company and no open-market activity affecting float or trading dynamics. Such grants marginally align director incentives with shareholders but are not financially material to Health Catalyst’s earnings, liquidity, or capital structure. I classify the event as neutral for investors and not impactful to the stock’s fundamental outlook.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KANE JOHN A

(Last) (First) (Middle)

C/O HEALTH CATALYST, INC.

10897 SOUTH RIVER FRONT PARKWAY, #300

(Street)

SOUTH JORDAN UT 84095

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Health Catalyst, Inc. [ HCAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2025		A		36,231(1)	A	$0.00	170,719(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units ("RSUs") granted pursuant to the Issuer's 2019 Stock Option and Incentive Plan (the "2019 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, the RSUs will fully vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the date of the next Annual Meeting of the Issuer's Stockholders.

2. Includes 3,493 shares that were not previously reported as held by the Reporting Person due to an inadvertent administrative error.

Remarks:

	/s/Benjamin Landry, as Attorney-in-Fact	07/10/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did HCAT director Julie Larson-Green acquire on 07/09/2025?

She was granted 36,231 RSUs, each convertible into one share of Health Catalyst common stock.

What is Julie Larson-Green’s total HCAT share ownership after the grant?

Her direct beneficial ownership increased to 111,251 shares.

When will the granted RSUs vest for Julie Larson-Green?

The RSUs fully vest on the earlier of one year from grant (07/09/2026) or the next HCAT annual meeting.

Did the Form 4 involve any open-market purchases or sales of HCAT stock?

No. The filing only reports a zero-cost RSU grant; no shares were bought or sold in the market.

Does this insider transaction materially affect Health Catalyst’s financials?

No. It is a routine equity compensation grant with immaterial financial impact on the company.